Search
15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference
October 26-31, 2020 | Virtual Global Conference
Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty, R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell
In the last week of October, consultants and specialist psychologists, nurses, scientists and…
15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference
October 26-31, 2020 | Virtual Global Conference
Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty, R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell
In the last week of October, consultants and specialist psychologists, nurses, scientists and…
The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read moreGenetic Predisposition to Blood Cancer (Rare diseases)
The objectives of the group are:
Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.
About us
Welcome to the family! Get to know the Young EHA Committee and learn how you can make a difference. Join Young EHA through a junior membership. Meet the Young EHA committee members:
Name: Mandy N.
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition
PRESS RELEASE
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition
The Hague, Wednesday 18, November, 2020
The field of cell and gene therapy is one of the most…
Chronic Myeloid Leukemia
The objective of this SWG is the cure of Chronic Myeloid Leukemia (CML) by cooperative research.
Read moreEHA-JSH Travel Grant
Financial support to help EHA members under 40 attend the Japanese Society of Hematology's Annual Meeting in October 2024.
Read moreThe ‘i4MDS’ consortium looks to the future at its second general meeting
The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- »